<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555618</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-850/CPH-003</org_study_id>
    <secondary_id>U1111-1174-1290</secondary_id>
    <secondary_id>JapicCTI-153019</secondary_id>
    <nct_id>NCT02555618</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants</brief_title>
  <official_title>A Randomized Double-Blind Parallel-Group Comparative Phase 2 Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of TAK-850 in Comparison With Influenza HA Vaccine in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of TAK-850
      administered subcutaneously as a single dose versus influenza HA vaccination in an
      exploratory manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 2, single dose study of TAK-850 (cell-culture derived TIV) administered
      subcutaneously in healthy Japanese adults, designed as a randomized, double-blind,
      parallel-group, comparative study to evaluate the immunogenicity and safety compared to an
      egg-derived TIV.

      The drug being tested in this study is called TAK-850. TAK-850 was tested in healthy
      volunteers. This study looked at immunogenicity and safety of TAK-850 (cell-derived) compared
      to an egg-derived influenza vaccine.

      The study enrolled 400 patients. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the two groups—which will remain undisclosed to the patient and
      study doctor during the study (unless there is an urgent medical need):

        -  TAK-850

        -  Influenza HA vaccine All participants received one injection. This single center trial
           was conducted in Japan. The overall time to participate in this study was 22 days.
           Participants made multiple visits to the clinic, including a final visit 21 days after
           the vaccination for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Seroconversion rate was measured by hemagglutination inhibition (HI) antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from the Baseline HI antibody titer in participants with a Baseline titer ≥10, or achieving an HI antibody titer of ≥40 in participants with a Baseline titer &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>Geometric mean titer (GMT) of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate of HI Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer of ≥40, was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in HI Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Geometric mean fold increase in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared with Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate of Single Radial Hemolysis (SRH) Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, as measured by single radial hemolysis (SRH) antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate of SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Geometric mean fold increase in SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate of HI Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Seroconversion rate, defined as the percentage of participants with a Baseline HI antibody titer of ≥10 achieving a minimal 4-fold increase, or a Baseline HI antibody titer of &lt;10 achieving a HI antibody titer of ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of HI Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>GMT of HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate of HI Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in HI Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Geometric mean fold increase in HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate of SRH Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SRH Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>GMT of SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate of SRH Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Days 1 and 22</time_frame>
    <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in SRH Antibody Titer (Vero-Derived Antigen)</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Geometric mean fold increase in SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>22 Days</time_frame>
    <description>Participants recorded solicited injection site and systemic adverse events in a Subject Diary. Solicited Locals AEs were: Injection Site Pain, Injection Site Redness, Injection Site Swelling, Injection Site Induration and Injection Site Ecchymosis. Solicited Systemic AEs were: Pyrexia, Malaise, Chills, Fatigue, Headache, Sweaty, Myalgia, Arthralgia, Nausea and Vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>22 days</time_frame>
    <description>Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Safety Laboratory Tests at Least Once Post Dose Reported as AEs</measure>
    <time_frame>22 Days</time_frame>
    <description>The percentage of participants with any abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout the study reported as AEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Influenza Infection</condition>
  <arm_group>
    <arm_group_label>TAK-850</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza HA Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TAK-850</intervention_name>
    <description>TAK-850 subcutaneous injection</description>
    <arm_group_label>TAK-850</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza HA vaccine</intervention_name>
    <description>Influenza HA vaccine subcutaneous injection</description>
    <arm_group_label>Influenza HA Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator or subinvestigator, the participant is capable of
             understanding and complying with protocol requirements.

          2. The participant signs and dates a written, informed consent form prior to the
             initiation of any study procedures.

          3. The participant is a healthy Japanese adult male or female.

          4. The participant is aged 20 to 49 years, inclusive, at the time of informed consent.

          5. The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m^2, inclusive,
             at the time of the eligibility evaluation.

          6. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agreed to routinely use adequate contraception from signing
             of the informed consent throughout the duration of the study.

        Exclusion Criteria:

          1. The participant has received any investigational compound within 4 months prior to
             injection of study vaccine.

          2. The participant has been vaccinated with seasonal influenza vaccine within 6 months
             prior to injection of study vaccine.

          3. The participant has a history of influenza infection within 6 months prior to
             injection of study vaccine.

          4. The participant has been vaccinated with TAK-850 before.

          5. The participant is a study site employee, an immediate family member of such an
             employee, or in a dependent relationship with a study site employee who is involved in
             the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under
             duress.

          6. The participant has uncontrolled, clinically significant manifestations of
             neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal,
             urologic, endocrine, or other disorders, which may impact the ability of the
             participant to participate or potentially confound the study results.

          7. The participant has an oral temperature &gt;= 37.5 °C prior to injection of study vaccine
             on Day 1.

          8. The participant has any medically diagnosed or suspected immune deficient condition.

          9. The participant has an immune compromising condition or disease, or is currently
             undergoing a form of treatment or was undergoing a form of treatment that can be
             expected to influence immune response within 30 days prior to injection of study
             vaccine. Such treatments include systemic or high dose inhaled corticosteroids (&gt; 800
             µg/day of beclomethasone dipropionate or equivalent; the use of inhaled and nasal
             steroids that do not exceed this level will be permitted), radiation therapy, and
             other immunosuppressive and cytotoxic drugs.

         10. The participant has received antipyretics within 4 hours prior to the injection of
             study vaccine.

         11. The participant has a history of Guillain-Barré Syndrome, demyelinating disorders
             (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis), or
             convulsions.

         12. The participant has a functional or surgical asplenia.

         13. The participant has a rash, other dermatologic conditions, or tattoos which may
             interfere with the evaluation of injection site reaction.

         14. The participant has a history of, or is infected with the Hepatitis B Virus (HBsAgs),
             Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).

         15. The participant has known hypersensitivity to any component of TAK-850 or Influenza HA
             Vaccine.

         16. The participant has a history of severe allergic reactions or anaphylaxis.

         17. The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse within 1 year prior to injection of study vaccine or is
             unwilling to agree to abstain from excessive alcohol and drugs throughout the study.

         18. The participant has received any blood products (blood transfusion or immunoglobulin)
             within 90 days prior to injection of study vaccine.

         19. The participant has received a live vaccine within 4 weeks (28 days) or an inactivated
             vaccine within 2 weeks (14 days) prior to injection of study vaccine.

         20. If female, the participant is pregnant or lactating or intending to become pregnant
             before signing of informed consent, during treatment, or within 12 weeks after
             injection of study vaccine; or intending to donate ova during this time period.

         21. The participant has donated whole blood &gt;= 200 mL within 4 weeks (28 days), &gt;= 400 mL
             within 12 weeks (84 days), &gt;= 800 mL within 52 weeks (364 days) or blood components
             within 2 weeks (14 days) prior to injection of study vaccine.

         22. The participant has abnormal laboratory values that suggest a clinically significant
             underlying disease at the assessment prior to the injection of study vaccine, or the
             participant has the following laboratory abnormalities: alanine aminotransferase (ALT)
             and/or aspartate aminotransferase (AST) more than 3 times the respective upper limits
             of normal.

         23. In the opinion of the investigator or subinvestigator, the participant is unlikely to
             comply with protocol requirements or is considered ineligible for any other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>November 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 24 September 2015 to 18 November 2015.</recruitment_details>
      <pre_assignment_details>Healthy Volunteers were enrolled equally in 1 of 2 groups, TAK-850 subcutaneous (SC) or Influenza hemagglutinin (HA) vaccine SC.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-850</title>
          <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
        <group group_id="P2">
          <title>Influenza HA Vaccine</title>
          <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor's Circumstances</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-850</title>
          <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
        <group group_id="B2">
          <title>Influenza HA Vaccine</title>
          <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="9.61"/>
                    <measurement group_id="B2" value="31.5" spread="9.46"/>
                    <measurement group_id="B3" value="31.4" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.3" spread="8.41"/>
                    <measurement group_id="B2" value="166.0" spread="8.32"/>
                    <measurement group_id="B3" value="166.2" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.67" spread="8.918"/>
                    <measurement group_id="B2" value="57.69" spread="7.937"/>
                    <measurement group_id="B3" value="58.18" spread="8.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.10" spread="1.912"/>
                    <measurement group_id="B2" value="20.86" spread="1.752"/>
                    <measurement group_id="B3" value="20.98" spread="1.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Infection within 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived)-A/H1N1 Strain</title>
          <description>HI Antibody Titer data is only available for N=199, 200 respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Titer &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer ≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HI Antibody Titer (Egg-derived)-A/H3N2 Strain</title>
          <description>HI Antibody Titer data is only available for N=199, 200 respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Titer &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer ≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HI Antibody Titer (Egg-derived)-B Strain</title>
          <description>HI Antibody Titer data is only available for N=199, 200 respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Titer &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer ≥40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroconversion rate was measured by hemagglutination inhibition (HI) antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from the Baseline HI antibody titer in participants with a Baseline titer ≥10, or achieving an HI antibody titer of ≥40 in participants with a Baseline titer &lt;10.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroconversion rate was measured by hemagglutination inhibition (HI) antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from the Baseline HI antibody titer in participants with a Baseline titer ≥10, or achieving an HI antibody titer of ≥40 in participants with a Baseline titer &lt;10.</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="40.627" upper_limit="54.918"/>
                    <measurement group_id="O2" value="46.0" lower_limit="38.948" upper_limit="53.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="24.795" upper_limit="38.088"/>
                    <measurement group_id="O2" value="36.0" lower_limit="29.350" upper_limit="43.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="22.472" upper_limit="35.463"/>
                    <measurement group_id="O2" value="26.0" lower_limit="20.068" upper_limit="32.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.983</ci_lower_limit>
            <ci_upper_limit>11.415</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.974</ci_lower_limit>
            <ci_upper_limit>4.403</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.082</ci_lower_limit>
            <ci_upper_limit>11.320</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</title>
        <description>Geometric mean titer (GMT) of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</title>
          <description>Geometric mean titer (GMT) of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.04" spread="5.256" lower_limit="30.955" upper_limit="49.228"/>
                    <measurement group_id="O2" value="43.77" spread="4.794" lower_limit="35.178" upper_limit="54.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.24" spread="3.098" lower_limit="204.264" upper_limit="280.206"/>
                    <measurement group_id="O2" value="241.88" spread="2.839" lower_limit="209.128" upper_limit="279.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.39" spread="4.558" lower_limit="17.300" upper_limit="26.439"/>
                    <measurement group_id="O2" value="22.62" spread="4.823" lower_limit="18.163" upper_limit="28.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.80" spread="4.643" lower_limit="52.282" upper_limit="80.314"/>
                    <measurement group_id="O2" value="84.93" spread="5.496" lower_limit="66.967" upper_limit="107.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.65" spread="3.898" lower_limit="20.380" upper_limit="29.812"/>
                    <measurement group_id="O2" value="25.34" spread="4.211" lower_limit="20.734" upper_limit="30.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.14" spread="3.652" lower_limit="58.523" upper_limit="84.063"/>
                    <measurement group_id="O2" value="65.89" spread="4.197" lower_limit="53.945" upper_limit="80.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7984</ci_lower_limit>
            <ci_upper_limit>1.2253</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5544</ci_lower_limit>
            <ci_upper_limit>1.0500</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8134</ci_lower_limit>
            <ci_upper_limit>1.3931</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate of HI Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer of ≥40, was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate of HI Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer of ≥40, was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" lower_limit="55.697" upper_limit="69.543"/>
                    <measurement group_id="O2" value="67.5" lower_limit="60.535" upper_limit="73.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="91.589" upper_limit="97.911"/>
                    <measurement group_id="O2" value="97.0" lower_limit="93.585" upper_limit="98.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="39.645" upper_limit="53.921"/>
                    <measurement group_id="O2" value="47.5" lower_limit="40.412" upper_limit="54.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" lower_limit="71.477" upper_limit="83.451"/>
                    <measurement group_id="O2" value="78.0" lower_limit="71.614" upper_limit="83.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="46.079" upper_limit="60.355"/>
                    <measurement group_id="O2" value="51.0" lower_limit="43.852" upper_limit="58.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="75.295" upper_limit="86.558"/>
                    <measurement group_id="O2" value="76.0" lower_limit="69.469" upper_limit="81.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in HI Antibody Titer (Egg-Derived Antigen)</title>
        <description>Geometric mean fold increase in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared with Baseline.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in HI Antibody Titer (Egg-Derived Antigen)</title>
          <description>Geometric mean fold increase in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared with Baseline.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="5.496" lower_limit="4.830" upper_limit="7.777"/>
                    <measurement group_id="O2" value="5.53" spread="5.353" lower_limit="4.373" upper_limit="6.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="4.268" lower_limit="2.474" upper_limit="3.711"/>
                    <measurement group_id="O2" value="3.75" spread="4.861" lower_limit="3.012" upper_limit="4.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="3.399" lower_limit="2.398" upper_limit="3.376"/>
                    <measurement group_id="O2" value="2.60" spread="3.356" lower_limit="2.196" upper_limit="3.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate of Single Radial Hemolysis (SRH) Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, as measured by single radial hemolysis (SRH) antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate of Single Radial Hemolysis (SRH) Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, as measured by single radial hemolysis (SRH) antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="43.591" upper_limit="57.894"/>
                    <measurement group_id="O2" value="44.0" lower_limit="37.006" upper_limit="51.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="31.890" upper_limit="45.839"/>
                    <measurement group_id="O2" value="47.5" lower_limit="40.412" upper_limit="54.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="25.262" upper_limit="38.611"/>
                    <measurement group_id="O2" value="34.0" lower_limit="27.467" upper_limit="41.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.020</ci_lower_limit>
            <ci_upper_limit>16.348</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.282</ci_lower_limit>
            <ci_upper_limit>0.901</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.461</ci_lower_limit>
            <ci_upper_limit>6.835</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>mm^2</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4939" spread="2.98861" lower_limit="27.88271" upper_limit="37.86773"/>
                    <measurement group_id="O2" value="33.7752" spread="2.85080" lower_limit="29.18491" upper_limit="39.08753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6792" spread="1.70398" lower_limit="77.67132" upper_limit="90.15189"/>
                    <measurement group_id="O2" value="79.9046" spread="1.46596" lower_limit="75.75435" upper_limit="84.28212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6364" spread="2.99866" lower_limit="20.27267" upper_limit="27.55832"/>
                    <measurement group_id="O2" value="24.8424" spread="2.79368" lower_limit="21.52683" upper_limit="28.66874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0742" spread="2.03848" lower_limit="43.51841" upper_limit="53.10687"/>
                    <measurement group_id="O2" value="53.5757" spread="1.87521" lower_limit="49.07889" upper_limit="58.48463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6214" spread="2.00064" lower_limit="41.40641" upper_limit="50.26551"/>
                    <measurement group_id="O2" value="46.3984" spread="1.89520" lower_limit="42.44118" upper_limit="50.72466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3848" spread="1.32537" lower_limit="71.51260" upper_limit="77.37238"/>
                    <measurement group_id="O2" value="75.8772" spread="1.32751" lower_limit="72.93820" upper_limit="78.93464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9559</ci_lower_limit>
            <ci_upper_limit>1.1473</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7862</ci_lower_limit>
            <ci_upper_limit>1.0241</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9273</ci_lower_limit>
            <ci_upper_limit>1.0364</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate of SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate of SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="63.484" upper_limit="76.601"/>
                    <measurement group_id="O2" value="73.0" lower_limit="66.285" upper_limit="79.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="93.553" upper_limit="98.886"/>
                    <measurement group_id="O2" value="98.5" lower_limit="95.679" upper_limit="99.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" lower_limit="56.725" upper_limit="70.495"/>
                    <measurement group_id="O2" value="67.0" lower_limit="60.017" upper_limit="73.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" lower_limit="84.322" upper_limit="93.348"/>
                    <measurement group_id="O2" value="93.5" lower_limit="89.141" upper_limit="96.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" lower_limit="82.588" upper_limit="92.118"/>
                    <measurement group_id="O2" value="88.5" lower_limit="83.245" upper_limit="92.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.232" upper_limit="99.987"/>
                    <measurement group_id="O2" value="99.0" lower_limit="96.435" upper_limit="99.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>Geometric mean fold increase in SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>Geometric mean fold increase in SRH antibody titer (egg-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5752" spread="2.83602" lower_limit="2.22603" upper_limit="2.97921"/>
                    <measurement group_id="O2" value="2.3658" spread="2.88645" lower_limit="2.04071" upper_limit="2.74262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0339" spread="2.54780" lower_limit="1.78464" upper_limit="2.31798"/>
                    <measurement group_id="O2" value="2.1566" spread="2.44635" lower_limit="1.90370" upper_limit="2.44314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6305" spread="1.81614" lower_limit="1.49999" upper_limit="1.77232"/>
                    <measurement group_id="O2" value="1.6353" spread="1.77973" lower_limit="1.50903" upper_limit="1.77222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate of HI Antibody Titer (Vero-Derived Antigen)</title>
        <description>Seroconversion rate, defined as the percentage of participants with a Baseline HI antibody titer of ≥10 achieving a minimal 4-fold increase, or a Baseline HI antibody titer of &lt;10 achieving a HI antibody titer of ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate of HI Antibody Titer (Vero-Derived Antigen)</title>
          <description>Seroconversion rate, defined as the percentage of participants with a Baseline HI antibody titer of ≥10 achieving a minimal 4-fold increase, or a Baseline HI antibody titer of &lt;10 achieving a HI antibody titer of ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="33.330" upper_limit="47.369"/>
                    <measurement group_id="O2" value="25.5" lower_limit="19.614" upper_limit="32.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="21.090" upper_limit="33.877"/>
                    <measurement group_id="O2" value="29.0" lower_limit="22.816" upper_limit="35.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="14.323" upper_limit="25.803"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.464" upper_limit="28.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>14.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.489</ci_lower_limit>
            <ci_upper_limit>23.577</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.614</ci_lower_limit>
            <ci_upper_limit>6.928</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for B-Strain.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.346</ci_lower_limit>
            <ci_upper_limit>5.579</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of HI Antibody Titer (Vero-Derived Antigen)</title>
        <description>GMT of HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of HI Antibody Titer (Vero-Derived Antigen)</title>
          <description>GMT of HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" spread="2.395" lower_limit="6.554" upper_limit="8.367"/>
                    <measurement group_id="O2" value="7.74" spread="2.346" lower_limit="6.876" upper_limit="8.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.88" spread="4.297" lower_limit="21.109" upper_limit="31.731"/>
                    <measurement group_id="O2" value="17.44" spread="3.978" lower_limit="14.387" upper_limit="21.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.93" spread="3.549" lower_limit="13.349" upper_limit="19.021"/>
                    <measurement group_id="O2" value="14.67" spread="3.722" lower_limit="12.211" upper_limit="17.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.65" spread="4.449" lower_limit="32.185" upper_limit="48.856"/>
                    <measurement group_id="O2" value="37.19" spread="5.313" lower_limit="29.465" upper_limit="46.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74" spread="2.826" lower_limit="9.289" upper_limit="12.419"/>
                    <measurement group_id="O2" value="10.13" spread="2.721" lower_limit="8.811" upper_limit="11.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.65" spread="4.004" lower_limit="17.833" upper_limit="26.284"/>
                    <measurement group_id="O2" value="20.30" spread="3.770" lower_limit="16.868" upper_limit="24.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1221</ci_lower_limit>
            <ci_upper_limit>1.9623</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7806</ci_lower_limit>
            <ci_upper_limit>1.4564</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8166</ci_lower_limit>
            <ci_upper_limit>1.3934</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate of HI Antibody Titer (Vero-Derived Antigen)</title>
        <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate of HI Antibody Titer (Vero-Derived Antigen)</title>
          <description>Seroprotection rate, defined as the percentage of participants with HI antibody titer ≥40, was measured by HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="8.298" upper_limit="17.984"/>
                    <measurement group_id="O2" value="11.0" lower_limit="7.023" upper_limit="16.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="47.079" upper_limit="61.334"/>
                    <measurement group_id="O2" value="40.0" lower_limit="33.155" upper_limit="47.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="31.890" upper_limit="45.839"/>
                    <measurement group_id="O2" value="32.0" lower_limit="25.596" upper_limit="38.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" lower_limit="59.827" upper_limit="73.331"/>
                    <measurement group_id="O2" value="60.0" lower_limit="52.854" upper_limit="66.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="14.323" upper_limit="25.803"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.464" upper_limit="28.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="36.230" upper_limit="50.408"/>
                    <measurement group_id="O2" value="46.0" lower_limit="38.948" upper_limit="53.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in HI Antibody Titer (Vero-Derived Antigen)</title>
        <description>Geometric mean fold increase in HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in HI Antibody Titer (Vero-Derived Antigen)</title>
          <description>Geometric mean fold increase in HI antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
          <population>FAS included all participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="4.066" lower_limit="2.873" upper_limit="4.252"/>
                    <measurement group_id="O2" value="2.25" spread="3.539" lower_limit="1.888" upper_limit="2.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="3.584" lower_limit="2.082" upper_limit="2.975"/>
                    <measurement group_id="O2" value="2.54" spread="3.593" lower_limit="2.122" upper_limit="3.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="3.046" lower_limit="1.725" upper_limit="2.355"/>
                    <measurement group_id="O2" value="2.00" spread="2.831" lower_limit="1.733" upper_limit="2.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate of SRH Antibody Titer (Vero-Derived Antigen)</title>
        <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate of SRH Antibody Titer (Vero-Derived Antigen)</title>
          <description>Seroconversion rate, defined as the percentage of participants with a Baseline SRH antibody titer of &gt;4 mm^2 achieving a minimal 50% increase, or a Baseline SRH antibody titer of ≤4 mm^2 achieving a SRH antibody titer of ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="18.352" upper_limit="30.677"/>
                    <measurement group_id="O2" value="23.0" lower_limit="17.358" upper_limit="29.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="34.294" upper_limit="48.385"/>
                    <measurement group_id="O2" value="42.0" lower_limit="35.074" upper_limit="49.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="36.230" upper_limit="50.408"/>
                    <measurement group_id="O2" value="40.0" lower_limit="33.155" upper_limit="47.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.195</ci_lower_limit>
            <ci_upper_limit>9.423</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for A/H3N2 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.369</ci_lower_limit>
            <ci_upper_limit>8.803</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is difference of seroconversion rate between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to -20%.</non_inferiority_desc>
            <param_type>Rate difference</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.406</ci_lower_limit>
            <ci_upper_limit>12.757</ci_upper_limit>
            <estimate_desc>TAK-850 - Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of SRH Antibody Titer (Vero-Derived Antigen)</title>
        <description>GMT of SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of SRH Antibody Titer (Vero-Derived Antigen)</title>
          <description>GMT of SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4041" spread="2.32428" lower_limit="6.58060" upper_limit="8.33056"/>
                    <measurement group_id="O2" value="7.7958" spread="2.26942" lower_limit="6.95397" upper_limit="8.73955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2670" spread="2.13276" lower_limit="14.63265" upper_limit="18.08382"/>
                    <measurement group_id="O2" value="15.2566" spread="2.32297" lower_limit="13.56496" upper_limit="17.15930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7055" spread="2.07033" lower_limit="17.79947" upper_limit="21.81561"/>
                    <measurement group_id="O2" value="19.1990" spread="2.14468" lower_limit="17.26128" upper_limit="21.35415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4796" spread="1.76234" lower_limit="30.00608" upper_limit="35.15703"/>
                    <measurement group_id="O2" value="33.2751" spread="1.85480" lower_limit="30.52867" upper_limit="36.26852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2050" spread="2.17963" lower_limit="25.29425" upper_limit="31.45059"/>
                    <measurement group_id="O2" value="28.2142" spread="2.23368" lower_limit="25.22323" upper_limit="31.55982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1647" spread="1.53822" lower_limit="49.11712" upper_limit="55.40139"/>
                    <measurement group_id="O2" value="49.7468" spread="1.55670" lower_limit="46.76970" upper_limit="52.91348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H1N1 Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9106</ci_lower_limit>
            <ci_upper_limit>1.2484</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for A/H3N2-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8686</ci_lower_limit>
            <ci_upper_limit>1.0969</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis is Geometric Mean Ratio between treatment groups for B Strain-Day 22.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin is set to 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9622</ci_lower_limit>
            <ci_upper_limit>1.1427</ci_upper_limit>
            <estimate_desc>TAK-850/Influenza HA Vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate of SRH Antibody Titer (Vero-Derived Antigen)</title>
        <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
        <time_frame>Days 1 and 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate of SRH Antibody Titer (Vero-Derived Antigen)</title>
          <description>Seroprotection rate, defined as the percentage of participants with SRH antibody titer ≥25 mm^2, was measured by SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination. Day 1 data is reported for reference.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="12.132" upper_limit="23.048"/>
                    <measurement group_id="O2" value="13.0" lower_limit="8.671" upper_limit="18.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="27.140" upper_limit="40.692"/>
                    <measurement group_id="O2" value="33.0" lower_limit="26.530" upper_limit="39.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="31.411" upper_limit="45.328"/>
                    <measurement group_id="O2" value="42.5" lower_limit="35.556" upper_limit="49.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" lower_limit="65.065" upper_limit="77.990"/>
                    <measurement group_id="O2" value="74.0" lower_limit="67.342" upper_limit="79.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="58.272" upper_limit="71.917"/>
                    <measurement group_id="O2" value="65.5" lower_limit="58.469" upper_limit="72.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain-Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="87.872" upper_limit="95.720"/>
                    <measurement group_id="O2" value="93.5" lower_limit="89.141" upper_limit="96.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in SRH Antibody Titer (Vero-Derived Antigen)</title>
        <description>Geometric mean fold increase in SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in SRH Antibody Titer (Vero-Derived Antigen)</title>
          <description>Geometric mean fold increase in SRH antibody titer (Vero-derived antigen) for each of the three strains, 21 days after vaccination, as compared with Baseline.</description>
          <population>FAS included all randomized participants who received vaccination with study vaccine. 1 participant in the TAK-850 group discontinued the study before completion of the specified final observation and is excluded.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1970" spread="2.03685" lower_limit="1.98906" upper_limit="2.42676"/>
                    <measurement group_id="O2" value="1.9570" spread="2.16354" lower_limit="1.75737" upper_limit="2.17938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6483" spread="1.71298" lower_limit="1.52879" upper_limit="1.77705"/>
                    <measurement group_id="O2" value="1.7332" spread="1.71960" lower_limit="1.60699" upper_limit="1.86926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8495" spread="1.91583" lower_limit="1.6881" upper_limit="2.02546"/>
                    <measurement group_id="O2" value="1.7632" spread="2.03032" lower_limit="1.59739" upper_limit="1.94618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Participants recorded solicited injection site and systemic adverse events in a Subject Diary. Solicited Locals AEs were: Injection Site Pain, Injection Site Redness, Injection Site Swelling, Injection Site Induration and Injection Site Ecchymosis. Solicited Systemic AEs were: Pyrexia, Malaise, Chills, Fatigue, Headache, Sweaty, Myalgia, Arthralgia, Nausea and Vomiting.</description>
        <time_frame>22 Days</time_frame>
        <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Participants recorded solicited injection site and systemic adverse events in a Subject Diary. Solicited Locals AEs were: Injection Site Pain, Injection Site Redness, Injection Site Swelling, Injection Site Induration and Injection Site Ecchymosis. Solicited Systemic AEs were: Pyrexia, Malaise, Chills, Fatigue, Headache, Sweaty, Myalgia, Arthralgia, Nausea and Vomiting.</description>
          <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweaty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
        <description>Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>22 days</time_frame>
        <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
          <description>Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal Safety Laboratory Tests at Least Once Post Dose Reported as AEs</title>
        <description>The percentage of participants with any abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout the study reported as AEs.</description>
        <time_frame>22 Days</time_frame>
        <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850</title>
            <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza HA Vaccine</title>
            <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Safety Laboratory Tests at Least Once Post Dose Reported as AEs</title>
          <description>The percentage of participants with any abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout the study reported as AEs.</description>
          <population>Safety Analysis Set included all participants who received vaccination with study vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver function test abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 Days</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-850</title>
          <description>A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
        <group group_id="E2">
          <title>Influenza HA Vaccine</title>
          <description>A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

